Sustainable models to overcome the challenging economics of antimicrobial R&D

Statement 17 Mar 2023

WHO Intergovernmental Negotiating Body (INB) intersessional briefing on “One Health and the Quadripartite”

On 17 March, IFPMA delivered a shortened version of the below statement at the WHO INB intersessional briefing on “Article 18: One Health and the Quadripartite” of the WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response (“WHO CA+”).

IFPMA comment on draft guidance on value of new antibiotics as part of UK “subscription-type” payment model

Geneva, April 12 2022 – Commenting on the publication of draft guidance from the National Institute for Health and Care Excellence (NICE) on antimicrobial drugs to become available as part of the UK’s innovative ‘subscription-type’ payment model, Thomas Cueni, IFPMA Director-General, said: “We welcome the results of the UK work to reward the full value...

Largest pharmaceutical industry-backed collective venture fund tackling antimicrobial resistance announces first portfolio investments

April 4, 2022, Geneva – The international trade body representing the biopharmaceutical industry (IFPMA) today welcomes the announcement of the AMR Action Fund’s first portfolio investments. The Fund is the world’s largest public-private partnership investing in biotech companies that are developing antibiotics, involving more than 20 leading biopharmaceutical companies who raised the majority of the...